Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chimerix ( (CMRX) ) has provided an announcement.
On March 4, 2025, Chimerix entered into a merger agreement with Jazz Pharmaceuticals, under which Jazz will acquire Chimerix for $8.55 per share, totaling approximately $935 million. This acquisition, expected to close in the second quarter of 2025, will allow Jazz to expand its oncology portfolio with dordaviprone, a treatment for H3 K27M-mutant diffuse glioma, which has no FDA-approved therapies. The transaction is anticipated to provide Jazz with a near-term commercial opportunity and strengthen its presence in the rare oncology space, while Chimerix shareholders are recommended to tender their shares.
More about Chimerix
Chimerix is a biopharmaceutical company focused on developing medicines to improve and extend the lives of patients with deadly diseases. Its most advanced clinical-stage development program is dordaviprone, aimed at treating H3 K27M-mutant glioma.
YTD Price Performance: 46.31%
Average Trading Volume: 5,377,009
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $446.1M
For detailed information about CMRX stock, go to TipRanks’ Stock Analysis page.